Ixaka’s CELTIC-19 granted Advanced Therapy Medicinal Product classification by EMA
Ixaka, an integrated cell and gene therapy company, says that Advanced Therapy Medicinal Product (ATMP) classification has been granted by the European Medicines Agency (EMA) for its Chemically Encapsulated Lentiviral vector for Targeted In Vivo CAR T-cell therapy (CELTIC-19) targeted nanoparticle (TNP) product.